From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Dechra Pharmaceuticals sorts out fat cats but is not on my buy list

By Chris Bailey | Monday 7 September 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


A couple of years ago I wrote on shares in Dechra Pharmaceuticals (DPHnot particularly complementarily, observing ‘I would not want to be paying a 30 times P/E ratio for that…even if its range of equine, cat and other animal pharmaceutical products continues to grow’. It has taken a while, but over recent weeks the stock has broken back above this letter. So on a quiet regulatory news day…what to make of this name following the publication of its full year results today?…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 10:13:10